Type 2 diabetes mellitus and its influence in the development of multidrug resistance tuberculosis in patients from southeastern Mexico

The effect size of type 2 diabetes mellitus on tuberculosis drug resistance and adverse treatment outcomes

“…In addition, T2DM has been recognized as an important risk factor for transmission, treatment failure, hospitalization, relapse, drug (DR), multidrug resistance (MDR), and delay in smear conversion (Baker et al, 2011;Dooley & Chaisson, 2009;Perez-Navarro et al, 2015;Thanh, Khue, Sy, & Strobel, 2015). However, these outcomes are not consistent across studies, perhaps due to variations in study populations (Balde et al, 2006; Magee et al, 2013;Shetty et al, 2006).…”

“…The increase in prevalence of T2DM has had a significant impact on tuberculosis comorbidity, with prevalence rates ranging from 10% to 30%, mainly affecting developing countries, including Latin America (Goldhaber-Fiebert, Jeon, Cohen, & Murray, 2011;IDF, 2015;Perez-Navarro, Fuentes-Dominguez, & Zenteno-Cuevas, 2015;Restrepo et al, 2011;Shetty, Shemko, Vaz, & D'Souza, 2006;Singla et al, 2006). The number of TB cases linked with T2DM increased by 134% in the last decade in Mexico.…”

“…Some studies report that T2DM increased two to three times the risk of TB (Dooley & Chaisson, 2009;Jeon & Murray, 2008;Perez-Navarro et al, 2015), and diminishes the success of treatment cure (Baker et al, 2011;Jimenez-Corona et al, 2013).…”

“…de.Vigilancia.Epidemiológica, 2013). Meanwhile, the World Health Organization (WHO) reported 9.5 million new cases of TB in 2014 and 1.5 million deaths.( WHO, 2015) In Mexico, the tuberculosis (TB) incidence was 23 per 100,000, reflecting a serious public health problem (Delgado-Sanchez et al, 2015).The increase in prevalence of T2DM has had a significant impact on tuberculosis comorbidity, with prevalence rates ranging from 10% to 30%, mainly affecting developing countries, including Some studies report that T2DM increased two to three times the risk of TB (Dooley & Chaisson, 2009;Jeon & Murray, 2008;Perez-Navarro et al, 2015), and diminishes the success of treatment cure (Baker et al, 2011;Jimenez-Corona et al, 2013).In addition, T2DM has been recognized as an important risk factor for transmission, treatment failure, hospitalization, relapse, drug (DR), multidrug resistance (MDR), and delay in smear conversion (Baker et al, 2011;Dooley & Chaisson, 2009;Perez-Navarro et al, 2015;Thanh, Khue, Sy, & Strobel, 2015). However, these outcomes are not consistent across studies, perhaps due to variations in study populations (Balde et al, 2006; Magee et al, 2013;Shetty et al, 2006).…”

“…(Perez-Navarro et al, 2015) To expand on these findings, the goal of the present study was to evaluate the effect size of T2DM on the TB clinical severity at the time of diagnosis and on its treatment outcomes.…”